Viloxazine ER Open-Label Extension in Adults: Sustained ADHD Gains, Modest Retention
This final open-label extension report describes long-term tolerability and symptom, executive function, and quality-of-life trajectories of a nonstimulant option in adults with attention-deficit/hyperactivity disorder (ADHD).
📅 Journal publication: Oct 2024(online Jan 10, 2025)·Last updated: Nov 15, 2026
Viloxazine ER shows long-term efficacy and safety for adult ADHD.
Viloxazine ER offers a nonstimulant option for adult ADHD, detailing its long-term safety and efficacy. During long-term use, viloxazine ER led to significant improvement in ADHD symptoms and quality of life, with 72.3% experiencing mild or moderate adverse events. While the study shows viloxazine's effectiveness, safety issues and high discontinuation rates due to adverse events and other causes remain concerns. Viloxazine ER shows promising improvements for adult ADHD with manageable safety profile over long-term use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Childress A, Cutler A, Adler L, Fry N, Asubonteng K, Formella A, Rubin J
Citation:Childress A, Cutler A, Adler L, et al. Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD. CNS spectrums. 2024;29(5):479-480. doi:10.1017/S1092852924001263